116 related articles for article (PubMed ID: 7794084)
21. Antihypertensive effects of a highly potent and long-acting angiotensin II subtype-1 receptor antagonist, (+-)-1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-1H- benzimidazole-7-carboxylate (TCV-116), in various hypertensive rats.
Inada Y; Wada T; Shibouta Y; Ojima M; Sanada T; Ohtsuki K; Itoh K; Kubo K; Kohara Y; Naka T
J Pharmacol Exp Ther; 1994 Mar; 268(3):1540-7. PubMed ID: 8138966
[TBL] [Abstract][Full Text] [Related]
22. Time course of losartan blockade of angiotensin II hypertension versus blockade of angiotensin II fast pressor effects.
Gorbea-Oppliger VJ; Melaragno MG; Potter GS; Petit RL; Fink GD
J Pharmacol Exp Ther; 1994 Nov; 271(2):804-10. PubMed ID: 7965799
[TBL] [Abstract][Full Text] [Related]
23. Juxtaglomerular cell hypertrophy and hyperplasia induced in rhesus monkeys by angiotensin II receptor antagonists.
Owen RA; Molon-Noblot S; Hubert MF; Siegl PK; Eydelloth RS; Keenan KP
Lab Invest; 1994 Oct; 71(4):543-51. PubMed ID: 7967510
[TBL] [Abstract][Full Text] [Related]
24. Characterization of renal angiotensin II receptors using subtype selective antagonists.
Edwards RM; Stack EJ; Weidley EF; Aiyar N; Keenan RM; Hill DT; Weinstock J
J Pharmacol Exp Ther; 1992 Mar; 260(3):933-8. PubMed ID: 1545405
[TBL] [Abstract][Full Text] [Related]
25. Pharmacological profile of a novel nonpeptide angiotensin II subtype 1 receptor antagonist, TCV-116.
Nishikawa K; Inada Y; Shibouta Y; Wada T; Ojima M; Kubo K; Naka T
Blood Press Suppl; 1994; 5():7-14. PubMed ID: 7889205
[TBL] [Abstract][Full Text] [Related]
26. In vitro pharmacology of L-158,809, a new highly potent and selective angiotensin II receptor antagonist.
Chang RS; Siegl PK; Clineschmidt BV; Mantlo NB; Chakravarty PK; Greenlee WJ; Patchett AA; Lotti VJ
J Pharmacol Exp Ther; 1992 Jul; 262(1):133-8. PubMed ID: 1625192
[TBL] [Abstract][Full Text] [Related]
27. [Angiotensin receptor blockers--significance for the therapy of hypertension].
Magometschnigg D
Wien Med Wochenschr; 2001; 151(7-8):153-6. PubMed ID: 11450162
[TBL] [Abstract][Full Text] [Related]
28. Angiotensin II receptor antagonists in the treatment of hypertension.
Kaplan NM
Am Fam Physician; 1999 Sep; 60(4):1185-90. PubMed ID: 10507747
[TBL] [Abstract][Full Text] [Related]
29. Nonpeptide angiotensin II receptor antagonists: a novel class of antihypertensive agents.
Timmermans PB; Carini DJ; Chiu AT; Duncia JV; Price WA; Wells GJ; Wong PC; Wexler RR; Johnson AL
Blood Vessels; 1990; 27(2-5):295-300. PubMed ID: 1978694
[TBL] [Abstract][Full Text] [Related]
30. [Nonpeptide angiotensin II receptor antagonists].
Nishikawa K
Tanpakushitsu Kakusan Koso; 1993 Aug; 38(11):1873-80. PubMed ID: 8210431
[No Abstract] [Full Text] [Related]
31. Pharmacological mechanism of angiotensin II receptor antagonists: implications for the treatment of elevated systolic blood pressure.
Brooks DP; Ruffolo RR
J Hypertens Suppl; 1999 Jun; 17(2):S27-32. PubMed ID: 10465064
[TBL] [Abstract][Full Text] [Related]
32. Angiotensin II receptor inhibition. A new therapeutic principle.
Messerli FH; Weber MA; Brunner HR
Arch Intern Med; 1996 Sep; 156(17):1957-65. PubMed ID: 8823149
[TBL] [Abstract][Full Text] [Related]
33. The renal profile of eprosartan.
Sica DA; Hollenberg NK
Pharmacotherapy; 1999 Apr; 19(4 Pt 2):86S-94S. PubMed ID: 10213527
[TBL] [Abstract][Full Text] [Related]
34. Pharmacological profile of valsartan, a non-peptide angiotensin II type 1 receptor antagonist. 1st communication: antihypertensive effects of valsartan in hypertensive models.
Yamamoto S; Hayashi N; Kometani M; Nakao K; Inukai T
Arzneimittelforschung; 1997 May; 47(5):604-12. PubMed ID: 9205773
[TBL] [Abstract][Full Text] [Related]
35. Concomitant angiotensin AT1 receptor antagonism and neprilysin inhibition produces omapatrilat-like antihypertensive effects without promoting tracheal plasma extravasation in the rat.
Hegde LG; Yu C; Renner T; Thibodeaux H; Armstrong SR; Park T; Cheruvu M; Olsufka R; Sandvik ER; Lane CE; Budman J; Hill CM; Klein U; Hegde SS
J Cardiovasc Pharmacol; 2011 Apr; 57(4):495-504. PubMed ID: 21297495
[TBL] [Abstract][Full Text] [Related]
36. Renal effects of angiotensin II receptor blockade and angiotensin-converting enzyme inhibition in healthy subjects.
Burnier M; Brunner HR
Exp Nephrol; 1996; 4 Suppl 1():41-6. PubMed ID: 9001896
[TBL] [Abstract][Full Text] [Related]
37. Telmisartan and carotid intima-media thickness regression: a class effect of angiotensin-receptor blockers?
Ntaios G; Savopoulos C; Hatzitolios A
Hypertens Res; 2008 Dec; 31(12):2187-8, author reply 2188. PubMed ID: 19139608
[No Abstract] [Full Text] [Related]
38. The diversified pharmacology of angiotensin II-receptor blockade.
Timmermans PB; Smith RD
Blood Press Suppl; 1996; 2():53-61. PubMed ID: 8913541
[TBL] [Abstract][Full Text] [Related]
39. Pharmacokinetic-pharmacodynamic relationships of three angiotensin II receptor antagonists in normal volunteers.
Burnier M; Buclin T; Biollaz J; Nussberger J; Waeber B; Brunner HR
Kidney Int Suppl; 1996 Jun; 55():S24-9. PubMed ID: 8743506
[No Abstract] [Full Text] [Related]
40. Nonpeptide angiotensin II receptor antagonists. XI. Pharmacology of EXP3174: an active metabolite of DuP 753, an orally active antihypertensive agent.
Wong PC; Price WA; Chiu AT; Duncia JV; Carini DJ; Wexler RR; Johnson AL; Timmermans PB
J Pharmacol Exp Ther; 1990 Oct; 255(1):211-7. PubMed ID: 2213556
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
